Synthesis of Silver Oxide Nanoparticles: A Novel Approach for Antimicrobial Properties and Biomedical Performance, Featuring Nodularia haraviana from the Cholistan Desert

Abstract

Nanoparticles have emerged as a prominent area of research in recent times, and silver nanoparticles (AgNPs) synthesized via phyco-technology have gained significant attention due to their potential therapeutic applications. Nodularia haraviana, a unique and lesser-explored cyanobacterial strain, holds substantial promise as a novel candidate for synthesizing nanoparticles. This noticeable research gap underscores the novelty and untapped potential of Nodularia haraviana in applied nanotechnology. A range of analytical techniques, including UV-vis spectral analysis, dynamic light scattering spectroscopy, scanning electron microscopy, Fourier transform infrared spectroscopy, and X-ray powder diffraction, were used to investigate and characterize the AgNPs. Successful synthesis of AgNPs was confirmed through UV-visible spectroscopy, which showed a surface plasmon resonance peak at 428 nm. The crystalline size of AgNPs was 24.1 nm. Dynamic light scattering analysis revealed that silver oxide nanoparticles had 179.3 nm diameters and a negative surface charge of −18 mV. Comprehensive in vitro pharmacogenetic properties revealed that AgNPs have significant therapeutic potential. The antimicrobial properties of AgNPs were evaluated by determining the minimum inhibitory concentration against various microbial strains. Dose-dependent cytotoxicity assays were performed on Leishmanial promastigotes (IC50: 18.71 μgmL−1), amastigotes (IC50: 38.6 μgmL−1), and brine shrimps (IC50: 134.1 μg mL−1) using various concentrations of AgNPs. The findings of this study revealed that AgNPs had significant antioxidant results (DPPH: 57.5%, TRP: 55.4%, TAC: 61%) and enzyme inhibition potential against protein kinase (ZOI: 17.11 mm) and alpha-amylase (25.3%). Furthermore, biocompatibility tests were performed against macrophages (IC50: >395 μg mL−1) and human RBCs (IC50: 2124 μg mL−1). This study showed that phyco-synthesized AgNPs were less toxic and could be used in multiple biological applications, including drug design and in the pharmaceutical and biomedical industries. This study offers valuable insights and paves the way for further advancements in AgNPs research.